Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model.
ORI-9020, a novel dinucleotide, evaluated in transgenic mice expressing hepatitis B virus (HBV), significantly reduced liver HBV DNA (P </= 0.001). Levels of HBeAg and HBsAg in serum and of HBcAg in liver were not affected by treatment. A minimal effective dosage was determined to be between 1.6 and 0.5 mg/kg of body weight/day, which was similar to that observed for adefovir dipivoxil.
Iyer
Radhakrishnan P
RP
Origenix Techonologies, Inc., St. Laurent, Quebec, Canada.
Roland
Arlene
A
Jin
Yi
Y
Mounir
Samir
S
Korba
Brent
B
Julander
Justin G
JG
Morrey
John D
JD
D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology*; D015139:Blotting, Southern; D004279:DNA, Viral / Q000097:blood; D006512:Hepatitis B Core Antigens / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics*; D007274:Injections, Intraperitoneal; D008099:Liver / Q000378:metabolism / Q000821:virology; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009841:Oligonucleotides / Q000008:administration & dosage / Q000494:pharmacology; D012367:RNA, Viral / Q000378:metabolism
D000998:Antiviral Agents; D004279:DNA, Viral; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; C487657:ORI 9020; D009841:Oligonucleotides; D012367:RNA, Viral